This study provides support for further studies on the usefulness of salivary C-reactive protein, mean platelet volume, and neutrophil-lymphocyte ratio as diagnostic markers for neonatal sepsis.

No abstract

Background and Objectives: Metabolic syndrome (MetS), one of the most serious global health issues, is considered chronic inflammatory states. Chemerin, Il-18 and Il-1 beta adipocytokines, plays an important role in linking Met S and inflammation. Few studies are conducted in Egypt to disclose the role of chemerin, Il-18 and Il-1 beta as combined biomarkers to increase its diagnostic accuracy. So the aim of our study was to evaluate the role of serum chemerin Il-18 and Il-1 beta as combined biomarkers for early detection of metabolic syndrome due to different genetic and environmental backgrounds. Methods:The study enrolled 171 participants divided into three groups, 57 children in each group. Group I:, 57 healthy control children group II obese children without metabolic syndrome and obese children with metabolic syndrome in Group 3 and. ranging in age from 5 to 17, were included in the study. Anthropometric and blood pressure measurements were taken of the participants.Fasting blood glucose, serum triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured. ELISA was used to assess the amounts of circulating chemerin.Results: Met S requirements were satisfied by 57 individuals. Abdominal obesity was the most common Met S predictor (84.2%), followed by impaired fasting blood sugar (73.7%), and then each of high triglyceride and low HDL (68.4%). Serum chemerin levels were significantly higher in Met S than in non-Met S obese and healthy subjects (1211.7 ± 1569 ng/ml VS 337.5 ± 34.8 ng/ml and 470.3 ± 475.8 ng/ml respectively, p ˂ 0.001). Serum chemerin levels were shown to be substantially linked with impaired fasting blood sugar (r = 0.398, p = 0.009) and low HDL (r = -0.386, p = 0.012) by correlation and multiple linear regression analysis. Conclusion:Circulating chemerin Il-18 and Il-1 beta , levels were associated with metabolic syndrome and could be independent markers for this disorder.

In this study, we aimed to evaluate serum cystatin C (sCysC) as an early predictor of acute kidney injury (AKI) in preterm neonates with respiratory distress syndrome (RDS). Sixty preterm neonates diagnosed with RDS and 40 healthy controls (28-36 weeks) admitted to the neonatal Intensive Care Unit were investigated. AKI was defined on the 3rd day of life (DOL-3) as an increase in serum creatinine (sCr) of >0.3 mg/dL from baseline (the lowest previous sCr). sCysC levels were measured on DOL-1, -3 and -7. Of the 60 neonates with RDS, 24 (40%) developed AKI. Five patients (79.17%) were classified as AKI Network (AKIN-1) and 19 patients (20.83%), as AKIN-2. At DOL-3, the mean sCysC values were significantly higher among neonates with RDS and AKI (1.68 ± 0.37) compared with controls (0.79 ± 0.83) and those with RDS and no AKI (0.85 ± 0.20) (P <0.001). sCysC levels significantly increased among neonates with AKI from DOL-3 to DOL-7 (P = 0.002). The sCr values showed no significant difference between those with RDS with AKI, RDS, and no AKI or control groups at DOL-1 and -3. Only as late as DOL-7, the mean values of sCr were higher among neonates with AKI compared with no AKI and controls (P <0.001). The receiver operating characteristic curves area under the curve was 0.97 for predicting the development of AKI within 72 h (P = 0.001). With the best cutoff value of ≥1.28 mg/L, the sensitivity and specificity of sCysC for detecting AKI within 72 h were 100 and 83.3%, respectively. In conclusion, sCysC is an early marker for AKI in neonates with RDS.

Introduction: It is agreed that insulin like growth factor 1 (IGF-